- Home
- FENC vs NBP Comparison
FENC vs NBP Comparison
Compare FENC & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FENC | NBP |
|---|---|---|
| Founded | 1996 | 2014 |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 230.8M | 225.5M |
| IPO Year | 2010 | N/A |
Fundamental Metrics
Financial Performance| Metric | FENC | NBP |
|---|---|---|
| Price | $10.49 | $1.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $14.50 | $9.00 |
| AVG Volume (30 Days) | 248.3K | ★ 780.1K |
| Earning Date | 05-12-2026 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $44,642,000.00 | N/A |
| Revenue This Year | $65.12 | N/A |
| Revenue Next Year | $41.08 | N/A |
| P/E Ratio | $1,031.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.65 | $1.46 |
| 52 Week High | $11.31 | $5.19 |
Technical Indicators
Market Signals| Indicator | FENC | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 59.80 | 52.94 |
| Support Level | $7.40 | $1.67 |
| Resistance Level | $11.31 | $1.95 |
| Average True Range (ATR) | 0.54 | 0.17 |
| MACD | -0.05 | 0.03 |
| Stochastic Oscillator | 61.64 | 51.89 |
Price Performance
Historical ComparisonAbout FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About NBP NovaBridge Biosciences American Depositary Shares
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.